Sensei Biotherapeutics, Inc. announced it will present initial safety and pharmacokinetic monotherapy clinical data from its Phase 1/2 trial of SNS- 101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), in a late-breaking poster presentation at the Society for Immunotherapy of Cancer (SITC) 38(th) Annual Meeting, being held in San Diego, Calif., from November 1 - 5, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6689 USD | -8.24% | +12.99% | -3.34% |
05-14 | Stephens Starts Sensei Biotherapeutics With Overweight Rating, $5 Price Target | MT |
05-09 | Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.34% | 16.78M | |
+16.49% | 122B | |
+21.73% | 115B | |
+22.18% | 26.64B | |
-21.81% | 19.91B | |
-16.89% | 16.32B | |
-18.81% | 15.49B | |
-44.74% | 15.52B | |
+62.72% | 14.83B | |
+3.09% | 13.67B |
- Stock Market
- Equities
- SNSE Stock
- News Sensei Biotherapeutics, Inc.
- Sensei Biotherapeutics, Inc. to Present Initial Clinical Data from Dose Escalation Trial of SNS 101 At 2023 SITC Annual Meeting